RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough lung cancer
Disease control OngoingThis early-phase trial tests whether adding bevacizumab to brigatinib can help people with ALK-positive non-small cell lung cancer whose disease has worsened on previous ALK-targeted therapy. The study enrolls just 5 patients and focuses on safety, side effects, and finding the b…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New immunotherapy combo aims to extend life in stage 3 lung cancer
Disease control OngoingThis phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New combo therapy shows promise for early lung cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation therapy helps prevent lung cancer from coming back in people with early-stage non-small cell lung cancer. About 140 participants will receive either radiation alone or radiation plus…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lung cancer drug combo tested in Mid-Stage trial
Disease control OngoingThis phase 2 trial tests two drugs, erlotinib and cabozantinib, given alone or together in 125 patients with advanced non-small cell lung cancer that does not have a common EGFR mutation. The goal is to see if the combination works better than either drug alone to slow cancer gro…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug combo aims to outsmart resistant lung cancer
Disease control OngoingThis early-phase trial tests a combination of two targeted drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goals are to find the safest dose and understand side effects.…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo targets Hard-to-Treat lung cancer
Disease control OngoingThis early-phase trial is testing two oral drugs, Sapanisertib and Telaglenastat, in 22 people with advanced non-small cell lung cancer that has spread to the brain or other organs. The drugs work by blocking key enzymes that cancer cells need to grow. The main goal is to find th…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to reboot immune system against lung cancer
Disease control OngoingThis study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab can help control advanced non-small cell lung cancer better than standard treatments. The drug combo aims to activate natural killer cells and boost the immune system's attack on cance…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo targets tough lung cancer in early trial
Disease control OngoingThis early-phase trial studies the safety and best dose of adding necitumumab to osimertinib for people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. About 138 participants will receive the combination to see if it is tolerable a…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo aims to outdo chemo for tough lung cancers
Disease control OngoingThis phase 3 trial tests whether a combination of two drugs—ramucirumab (which blocks blood vessel growth to tumors) and pembrolizumab (which boosts the immune system)—works better than standard chemotherapy for people with advanced or recurrent non-small cell lung cancer that ha…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can adding surgery or radiation to a targeted pill slow lung cancer better?
Disease control OngoingThis study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug targets rare lung cancer mutation in advanced disease
Disease control OngoingThis phase II trial tests the drug selpercatinib (LOXO-292) in 124 people with stage IV or recurrent non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug works by blocking enzymes that help cancer cells grow. Researchers are measuring how ma…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Nanoparticles could supercharge radiation against returning lung tumors
Disease control OngoingThis early-phase trial tests whether adding NBTXR3 nanoparticles to radiation therapy can safely treat inoperable non-small cell lung cancer that has come back after prior radiation. The nanoparticles are designed to concentrate radiation energy inside tumor cells, potentially ki…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Lung cancer radiation gets a precision boost: trial aims to hit tumors harder, spare healthy tissue
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cocktail of drugs shows promise for tough lung cancer
Disease control OngoingThis early-phase trial is testing a combination of four drugs—ensartinib, two chemotherapy drugs, and a targeted antibody—in 12 people with advanced ALK-positive non-small cell lung cancer. The goal is to find the safest dose and see how well the combination controls the disease.…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Vitamin a derivative combined with immunotherapy shows promise in early lung cancer trial
Disease control OngoingThis early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose an…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New combo aims to control advanced lung cancer
Disease control OngoingThis study tests a combination of two drugs—pembrolizumab (an immunotherapy) and trametinib (a targeted therapy)—in people with advanced non-small cell lung cancer that has come back or spread. The goal is to see if the combination is safe and can shrink or control tumors. Partic…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New combo attack on lung cancer: targeted drug plus surgery or radiation
Disease control OngoingThis early-phase trial is testing whether adding local treatments like surgery or radiation to the targeted drug brigatinib can help control advanced ALK-positive non-small cell lung cancer. About 35 people who have not yet taken other targeted therapies will receive brigatinib f…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cord blood cells engineered to fight lung cancer enter human testing
Disease control OngoingThis early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The treatment uses immune cells from umbilical cord blood that are genetically modified to better recognize and attack cancer ce…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Blood test may help cancer patients avoid nerve damage from chemo
Knowledge-focused TerminatedThis pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC